Spermosens calls SEK 4.85 million under previously announced Capital Facility

Spermosens AB (publ) ("Spermosens" or the "Company") hereby announces that the Board of Directors has today resolved to call capital under the capital facility of SEK 4.85 million that was announced on 7 May 2026 and subsequently approved by the Annual General Meeting on 18 June 2026. In accordance with the terms of the Capital Facility, the full available amount of SEK 4.85 million has been called. The capital will be contributed to the Company through the issuance of units to the investors participating in the Capital Facility.

Summary of key terms

- The total amount called under the Capital Facility is SEK 4.85 million.
- The capital will be contributed to the Company through the issuance of units to the investors participating in the Capital Facility.
- Each unit will consist of one (1) share and one (1) warrant issued free of charge.
- The subscription price for the shares will correspond to a fifteen (15) per cent discount to the volume-weighted average price (VWAP) of the Company's shares during the ten (10) trading days following today's call of capital, however not lower than the quota value of the shares.
- Each warrant will entitle the holder to subscribe for one (1) new share at a subscription price of SEK 0.025 per share and will have a term of three (3) years.

Timetable and Extraordinary General Meeting

A measurement period of ten (10) trading days will commence on the trading day following today's call of capital. During this period, the volume-weighted average price (VWAP) of the Company's shares will be determined.

Following the expiry of the measurement period, the Board of Directors will, no later than one (1) week thereafter, resolve on the directed issue of units to the investors participating in the Capital Facility.

As the participation by Chairman of the Board Ulrik Spork and Chief Executive Officer Tore Duvold in the Capital Facility is subject to the provisions of Chapter 16 of the Swedish Companies Act (the Swedish "Leo Rules"), the Board of Directors will submit a proposal to an Extraordinary General Meeting regarding a separate directed issue of units to Ulrik Spork and Tore Duvold on terms corresponding to those applicable to the other investors participating in the Capital Facility. Notice of the Extraordinary General Meeting will be published in connection with the Board of Directors' resolutions on the directed issues.

For further information, please contact:

Tore Duvold, CEO
E-mail: info@spermosens.com

About Spermosens AB

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.